IDH1 Inhibitor
AG-120 for Solid Tumors
This trial is testing a new drug, AG-120, to see if it is safe and effective in treating patients with advanced solid tumors that have a specific genetic mutation. The trial has two parts: a dose escalation phase to find the best dose of the drug, and a dose expansion phase to further test the drug's safety and effectiveness.